This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. The subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day according to the requirements of clinical trial scheme.

Key Inclusion Criteria:

• 18-40 years old (including 18 and 40 years old);
• Investigator's Global Assessment of subject at baseline period was at 3-4.
• Facial skin lesions of subject need counting as follows: 30 ~ 75 inflammatory lesions (the total number of papules, pustules and nodules is 30 ~ 75, including no more than 2 nodules), 30 ~ 100 non-inflammatory lesions (the total number of open and closed comedones is 30 ~ 100);

Key Exclusion Criteria:

• Known to be allergic or hypersensitive to ASC40 tablets;
• Facial nodules of subject is more than 2 facial nodules
• The subject with cystic acne
• Subject with secondary acne such as occupational acne (e.g., chloroacne) and acne caused by corticosteroids (e.g., chloroacne or acne caused by drugs);
• Serum AST, ALT≥3ULN and Cr exceeded the upper limit of normal range